First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.

J. Rodon Ahnert,J. Baselga,Emiliano Calvo,Joan Seoane,Irene Brana,Elisabet Sicart,Ivelina Gueorguieva,Ann Cleverly,Michael Lahn,Sada Pillay,Matthias Holdhoff,Jaishri Blakeley,Michael A. Carducci

First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.

2011

J. Rodon Ahnert
J. Baselga
Emiliano Calvo
Joan Seoane
Irene Brana
Elisabet Sicart
Ivelina Gueorguieva
Ann Cleverly
Michael Lahn
Sada Pillay
Matthias Holdhoff
Jaishri Blakeley
Michael A. Carducci

3011 Background: Activated TGF-b signaling has been associated with poor survival in several tumors, including glioma, hepatocellular and pancreatic cancer. TGF-b inhibitors are expected to improve...

Keywords:

Transforming growth factor beta receptor I
Refractory
Glioma
Cancer research
Kinase
Medicine
treatment refractory
Transforming growth factor
Pancreatic cancer
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations